NASDAQ:BBI - Brickell Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 1,233.33 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.15
+0.30 (1.20%)

This chart shows the closing price for BBI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Brickell Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BBI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BBI

Analyst Price Target is $2.00
▲ +1,233.33% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Brickell Biotech in the last 3 months. The average price target is $2.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,233.33% upside from the last price of $0.15.

This chart shows the closing price for BBI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Brickell Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022Lake Street CapitalDowngradeBuy ➝ HoldHigh
3/8/2022William BlairInitiated CoverageOutperformHigh
1/18/2022HC WainwrightInitiated CoverageBuy$2.00High
4/26/2021OppenheimerReiterated RatingBuyHigh
8/28/2020Lake Street CapitalInitiated CoverageBuy$6.00High
8/25/2020OppenheimerInitiated CoverageOutperform$5.00High
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/26/2022

Current Sentiment

  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Brickell Biotech logo
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $0.15
Low: $0.14
High: $0.15

50 Day Range

MA: $0.25
Low: $0.15
High: $0.39

52 Week Range

Now: $0.15
Low: $0.14
High: $1.04

Volume

7,907,582 shs

Average Volume

7,612,160 shs

Market Capitalization

$17.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Brickell Biotech?

The following Wall Street research analysts have issued reports on Brickell Biotech in the last year: HC Wainwright, Lake Street Capital, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BBI.

What is the current price target for Brickell Biotech?

0 Wall Street analysts have set twelve-month price targets for Brickell Biotech in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 1,233.3%.
View the latest price targets for BBI.

What is the current consensus analyst rating for Brickell Biotech?

Brickell Biotech currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BBI will outperform the market and that investors should add to their positions of Brickell Biotech.
View the latest ratings for BBI.

How do I contact Brickell Biotech's investor relations team?

Brickell Biotech's physical mailing address is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. The company's listed phone number is (720) 505-4755 and its investor relations email address is [email protected] The official website for Brickell Biotech is www.brickellbio.com. Learn More about contacing Brickell Biotech investor relations.